Latest Conference Articles

Shepherd Says Molecular Pathology Has Made EGFR+ NSCLC Example for Field Advancements

Molecular pathologists have helped to advance translational research significantly for lung cancer over the past 10 years; nowhere is that more obvious than in EGFR-mutant non-small cell lung cancer.

Immunotherapy Requires Precision Medicine Approach for NSCLC

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

Dr. Langer on Practice-Changing PACIFIC Data in Stage III NSCLC

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the practice-changing data from the PACIFIC trial, which evaluated durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

Dr. Bazhenova on Prevalence of NTRK Mutations in NSCLC and Emerging Treatments

Lyudmila A. Bazhenova, MD, medical oncologist professor of medicine, University of California, San Diego, discusses the prevalence of NTRK mutations in non–small cell lung cancer.

Targeted Therapy Options Expanding for NSCLC

Several novel targeted therapies are emerging for a growing number of driver mutations in lung cancer, with multiple targeted agents now confirmed standards of care.

Dr. Hobbs on the Updated NCCN Guidelines in CML

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the updated NCCN guidelines in chronic myeloid leukemia (CML).

Dr. Brander on the Treatment Landscape for Patients With High-Risk CLL

Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

Dr. Lonial Discusses Emerging Agents in Relapsed/Refractory Myeloma

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses emerging agents in relapsed/refractory multiple myeloma.

Dr. Smith Discusses Brentuximab Vedotin in CTCL

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma.

Ansell Discusses Combination Potential in Hodgkin Lymphoma

Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.

Lonial Lays Out Optimal Sequence Strategies for Relapsed/Refractory Myeloma

Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.

US Versus European Opinions on Upfront Therapy in Hodgkin Lymphoma

United States’ versus European perspectives on bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma, along with the value of interim positron emission tomography, were discussed at the 2018 Pan Pacific Lymphoma Conference.

Expert Shares Insights on CLL Treatment Paradigm

Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.

Immunotherapy at the Forefront of ALL Treatment, Expert Says

Major advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.

Immunotherapy Treatment Options Continue to Grow in Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.

Dr. Roschewski Discusses DA-EPOCH-R in Burkitt Lymphoma

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.

Dr. Kahl Discusses Polatuzumab Vedotin in Lymphoma

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate polatuzumab vedotin in lymphoma.

Bleomycin Linked to High Rate of Pulmonary Disorders among Patients with Hodgkin Lymphoma

A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.

Treatment Options for CD30-Positive PTCL Subtypes

Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.

The Future of Myeloma Induction May Be Quadruplets

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

Dr. Maloney Discusses Updates With CAR T-Cell Therapy in NHL

David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses updates with CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Vose Discusses the Importance of Genomic Analysis in NHL

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.

Navigating the Toxicities of Novel-Novel Combinations in Lymphoma

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.

Kahl Shares Antibody-Drug Conjugate Updates in Lymphoma

With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.

Key Characteristics Emerging for CAR T Cell Success

An effective lymphodepletion strategy is critical to success with chimeric antigen receptor T-cell therapy, but also the choice of patients and even the cells used for CAR T cell manufacturing should be made with care.

Dr. Pinilla-Ibarz Discusses Advancements in CML

Javier A. Pinilla-Ibarz, MD, PhD senior member, Moffit Cancer Center, discusses the recent advances in chronic myeloid leukemia (CML). Pinilla-Ibarz says that he and colleagues do not expect much in the field after other recent advancements, but he is still surprised to see what is being concentrated on today.

Dr. Madduri on SWOG S0777 in Multiple Myeloma

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.

Despite New Treatments in CLL, Comparative Data and Guidance Slow to Emerge

With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.

Pembrolizumab Data Reviewed in Classical Hodgkin Lymphoma

George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.

CAR T-cell Therapies Offer Hope for DLBCL

Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.